RU2430718C2 - Фармацевтическая композиция для перорального введения - Google Patents
Фармацевтическая композиция для перорального введения Download PDFInfo
- Publication number
- RU2430718C2 RU2430718C2 RU2009101498/15A RU2009101498A RU2430718C2 RU 2430718 C2 RU2430718 C2 RU 2430718C2 RU 2009101498/15 A RU2009101498/15 A RU 2009101498/15A RU 2009101498 A RU2009101498 A RU 2009101498A RU 2430718 C2 RU2430718 C2 RU 2430718C2
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- oil
- platinum complex
- suspension
- composition according
- Prior art date
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 title abstract description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 92
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 46
- 239000000725 suspension Substances 0.000 claims abstract description 28
- 239000000126 substance Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000002245 particle Substances 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 5
- 239000011707 mineral Substances 0.000 claims abstract description 5
- 235000013311 vegetables Nutrition 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000002775 capsule Substances 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 239000007903 gelatin capsule Substances 0.000 claims description 8
- 235000019483 Peanut oil Nutrition 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 239000000312 peanut oil Substances 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 150000002314 glycerols Chemical class 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 2
- IFXJQZZLXIKKNB-UHFFFAOYSA-J 1-adamantylhydrazine;dichloroplatinum(2+);diacetate Chemical compound Cl[Pt+2]Cl.CC([O-])=O.CC([O-])=O.C1C(C2)CC3CC2CC1(NN)C3 IFXJQZZLXIKKNB-UHFFFAOYSA-J 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000003057 platinum Chemical class 0.000 description 11
- 239000006186 oral dosage form Substances 0.000 description 7
- -1 polyoxyethylene Polymers 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 235000021400 peanut butter Nutrition 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- NPTLAYTZMHJJDP-KTKRTIGZSA-N [3-[3-[3-[3-[3-[3-[3-[3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropoxy]-2-hydroxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)COCC(O)CO NPTLAYTZMHJJDP-KTKRTIGZSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZPV2006-402 | 2006-06-20 | ||
| CZ20060402A CZ300424B6 (cs) | 2006-06-20 | 2006-06-20 | Farmaceutická kompozice pro perorální podání |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009101498A RU2009101498A (ru) | 2010-07-27 |
| RU2430718C2 true RU2430718C2 (ru) | 2011-10-10 |
Family
ID=38819283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009101498/15A RU2430718C2 (ru) | 2006-06-20 | 2007-06-20 | Фармацевтическая композиция для перорального введения |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7767709B2 (cs) |
| EP (1) | EP2034957B1 (cs) |
| JP (1) | JP2009541227A (cs) |
| KR (1) | KR20090048436A (cs) |
| CN (1) | CN101505727A (cs) |
| AT (1) | ATE478655T1 (cs) |
| AU (1) | AU2007262493A1 (cs) |
| CZ (1) | CZ300424B6 (cs) |
| DE (1) | DE602007008724D1 (cs) |
| DK (1) | DK2034957T3 (cs) |
| ES (1) | ES2358205T3 (cs) |
| IL (1) | IL196100A0 (cs) |
| PL (1) | PL2034957T3 (cs) |
| PT (1) | PT2034957E (cs) |
| RU (1) | RU2430718C2 (cs) |
| SI (1) | SI2034957T1 (cs) |
| UA (1) | UA93404C2 (cs) |
| WO (1) | WO2007147371A2 (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2004964A3 (cs) * | 2004-09-14 | 2006-03-15 | Pliva-Lachema A. S. | Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
| AU2013267359C1 (en) * | 2012-05-31 | 2016-09-29 | Allergan pharmaceuticals International Ltd. | Formulations and methods for vaginal delivery of antiprogestins |
| CN108368143B (zh) | 2015-12-09 | 2022-02-01 | 维也纳医科大学 | 用于癌症疗法的单马来酰亚胺官能化的铂化合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0423707A2 (en) * | 1989-10-17 | 1991-04-24 | Bristol-Myers Squibb Company | Platinum complexes |
| EP1319403A1 (en) * | 2000-08-11 | 2003-06-18 | Sumitomo Pharmaceuticals Company, Limited | Remedies for cisplatin-tolerant cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8328218D0 (en) * | 1983-10-21 | 1983-11-23 | Johnson Matthey Plc | Oral compositions |
| ATE113054T1 (de) * | 1988-02-02 | 1994-11-15 | Johnson Matthey Inc | Pt(iv) komplexe. |
| JPH02290813A (ja) * | 1989-04-28 | 1990-11-30 | Sumitomo Pharmaceut Co Ltd | ヨード化油および脂溶性白金（２）錯体からなる制癌組成物 |
| US5656290A (en) * | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| JP3715650B2 (ja) * | 1995-02-28 | 2005-11-09 | 喜徳 喜谷 | 新規白金（ｉｖ）錯体、その製造方法及びそれを含む制癌剤 |
| US5736151A (en) * | 1996-12-09 | 1998-04-07 | Pharmacia & Upjohn Company | Antibiotic oil suspensions |
| CN1096263C (zh) * | 1997-02-05 | 2002-12-18 | 法玛西雅厄普约翰美国公司 | 高不溶性铂配合物的脂质复合物和脂质体 |
| JPH10265380A (ja) * | 1997-03-17 | 1998-10-06 | Bristol Myers Squibb Co | 抗ガン剤 |
| KR100246722B1 (ko) * | 1997-12-30 | 2000-04-01 | 박호군 | 경구용 백금 착화합물 항암제 및 그 제조방법 |
| CZ288912B6 (cs) * | 1998-05-27 | 2001-09-12 | Lachema, A. S. | Komplex platiny v oxidačním čísle IV, způsob přípravy tohoto komplexu, tento komplex jako léčivo a farmaceutická kompozice tento komplex obsahující |
| PE20001227A1 (es) * | 1998-10-30 | 2000-11-06 | Hoffmann La Roche | Procesos para producir una composicion de isotretinoina |
| US20030082102A1 (en) * | 2001-06-25 | 2003-05-01 | Court Wayne S. | Radioactive platinum complexes for cancer treatment |
| CA2456746A1 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Method for treating lung cancers |
| US20040156889A1 (en) * | 2002-11-26 | 2004-08-12 | Ning Hu | Method of drug loading in liposomes by gradient |
| CZ296045B6 (cs) * | 2003-03-31 | 2005-12-14 | Pliva-Lachema A. S. | Farmaceutická kompozice obsahující jako účinnou látku komplex čtyřmocné platiny a způsob její výroby |
| CZ295584B6 (cs) * | 2004-02-12 | 2005-08-17 | Pliva-Lachema A. S. | Farmaceutická kompozice obsahující jako účinnou látku platinový komplex a způsob výroby této kompozice |
| WO2006055352A2 (en) * | 2004-11-08 | 2006-05-26 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
| ATE431140T1 (de) * | 2005-03-11 | 2009-05-15 | Gpc Biotech Ag | Antiproliferative kombinations-therapie mit satraplatin oder jm118 und docetaxel |
| EP1792622A1 (en) * | 2005-11-11 | 2007-06-06 | GPC Biotech AG | Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues |
| CZ300120B6 (cs) * | 2006-06-20 | 2009-02-11 | Pliva - Lachema A. S. | Farmaceutická kompozice pro injekcní podání |
| CZ300590B6 (cs) * | 2006-06-20 | 2009-06-24 | Pliva - Lachema A. S. | Farmaceutická kompozice pro injekcní podání |
-
2006
- 2006-06-20 CZ CZ20060402A patent/CZ300424B6/cs not_active IP Right Cessation
-
2007
- 2007-06-20 JP JP2009515691A patent/JP2009541227A/ja active Pending
- 2007-06-20 PL PL07721847T patent/PL2034957T3/pl unknown
- 2007-06-20 WO PCT/CZ2007/000058 patent/WO2007147371A2/en active Application Filing
- 2007-06-20 EP EP07721847A patent/EP2034957B1/en not_active Withdrawn - After Issue
- 2007-06-20 AT AT07721847T patent/ATE478655T1/de not_active IP Right Cessation
- 2007-06-20 UA UAA200814645A patent/UA93404C2/ru unknown
- 2007-06-20 SI SI200730418T patent/SI2034957T1/sl unknown
- 2007-06-20 CN CNA2007800308665A patent/CN101505727A/zh active Pending
- 2007-06-20 RU RU2009101498/15A patent/RU2430718C2/ru active IP Right Revival
- 2007-06-20 ES ES07721847T patent/ES2358205T3/es active Active
- 2007-06-20 DK DK07721847.7T patent/DK2034957T3/da active
- 2007-06-20 PT PT07721847T patent/PT2034957E/pt unknown
- 2007-06-20 KR KR1020097001188A patent/KR20090048436A/ko not_active Ceased
- 2007-06-20 US US12/305,337 patent/US7767709B2/en active Active
- 2007-06-20 AU AU2007262493A patent/AU2007262493A1/en not_active Abandoned
- 2007-06-20 DE DE602007008724T patent/DE602007008724D1/de active Active
-
2008
- 2008-12-21 IL IL196100A patent/IL196100A0/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0423707A2 (en) * | 1989-10-17 | 1991-04-24 | Bristol-Myers Squibb Company | Platinum complexes |
| EP1319403A1 (en) * | 2000-08-11 | 2003-06-18 | Sumitomo Pharmaceuticals Company, Limited | Remedies for cisplatin-tolerant cancer |
Non-Patent Citations (2)
| Title |
|---|
| CERMANOVA J. «Single-dose pharmacokinetics of a novel oral platinum cytostatic drug([OC-6-43]-bis[acetato][1-adamantylamine]-amminedichloroplatinum [IV]) in pigs», Methods and Findings in Experimental and Clinical Pharmacology Vol.26, №9, 2004, pp.679-685, abstract. * |
| MCKEAGE, M.J. «Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer», Journal of Clinical Oncology Vol.15, №7, 1997, pp.2691-2700, abstract. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2006402A3 (cs) | 2007-12-27 |
| CN101505727A (zh) | 2009-08-12 |
| AU2007262493A1 (en) | 2007-12-27 |
| WO2007147371A2 (en) | 2007-12-27 |
| UA93404C2 (ru) | 2011-02-10 |
| JP2009541227A (ja) | 2009-11-26 |
| RU2009101498A (ru) | 2010-07-27 |
| WO2007147371A3 (en) | 2008-04-17 |
| DE602007008724D1 (de) | 2010-10-07 |
| PT2034957E (pt) | 2010-11-30 |
| ES2358205T3 (es) | 2011-05-06 |
| CZ300424B6 (cs) | 2009-05-13 |
| ATE478655T1 (de) | 2010-09-15 |
| PL2034957T3 (pl) | 2011-04-29 |
| IL196100A0 (en) | 2009-09-01 |
| EP2034957B1 (en) | 2010-08-25 |
| SI2034957T1 (sl) | 2011-03-31 |
| US7767709B2 (en) | 2010-08-03 |
| EP2034957A2 (en) | 2009-03-18 |
| US20100010083A1 (en) | 2010-01-14 |
| WO2007147371B1 (en) | 2008-06-19 |
| DK2034957T3 (da) | 2010-12-20 |
| KR20090048436A (ko) | 2009-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101759750B1 (ko) | 친수성 약물의 자가 미세-유화 경구용 약제 조성물 및 이의 제조 방법 | |
| KR101716878B1 (ko) | 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법 | |
| JP2004504342A (ja) | 極めて水不溶性の脂肪親和性薬剤用の自己乳化性ドラッグデリバリーシステム | |
| JP2006501134A (ja) | 高い生物学的利用能を有する、経口活性タキサン誘導体の医薬組成物 | |
| US20090069411A1 (en) | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids | |
| RU2430718C2 (ru) | Фармацевтическая композиция для перорального введения | |
| US20100076070A1 (en) | Forskolin Compositions and Methods For Administration | |
| AU2004262496B2 (en) | Semi-solid formulations for the oral administration of taxoids | |
| KR101859200B1 (ko) | 모노아세틸디아실글리세롤 화합물의 경구 투여용 조성물 및 고형 제제 | |
| AU2011276552A1 (en) | Oral formulation of kinase inhibitors | |
| EP1596839A2 (en) | Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier | |
| KR20200036143A (ko) | 자가미세유화 약물전달시스템을 이용한 난용성 약물의 약학적 제제 | |
| CN109381427A (zh) | 一种寡聚乙二醇修饰的多西他赛衍生物的注射剂 | |
| KR20110136256A (ko) | 플루비프로펜을 함유하는 자가 유화 약물 전달 조성물 | |
| CN112353759A (zh) | 菲并吲哚里西啶生物碱衍生物纳米自乳化组合物及其制备方法 | |
| HK1091743B (en) | Semi-solid formulations for the oral administration of taxoids | |
| HK1028879B (en) | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation | |
| HK1028879A1 (en) | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation | |
| HK1165999A (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140621 |
|
| NF4A | Reinstatement of patent |
Effective date: 20150610 |